<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366077</url>
  </required_header>
  <id_info>
    <org_study_id>CSUB0144</org_study_id>
    <nct_id>NCT03366077</nct_id>
  </id_info>
  <brief_title>Double-blinded, Randomized, Placebo-controlled Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection</brief_title>
  <official_title>A Double-blinded, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection (UTI) in Adult Women Recently Treated for UTI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGaia AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infections (UTIs) are the most common bacterial infections in women, with about&#xD;
      50% of women experiencing at least one UTI in their lifetime.&#xD;
&#xD;
      The main pharmacological treatments of cystitis usually involve the use of antibiotics, in&#xD;
      particular quinolones (such as ciprofloxacin and levofloxacin), fosfomycin, second-generation&#xD;
      and third-generation cephalosporins, and b-lactam antibiotics associated with b-lactamase&#xD;
      inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blinded, randomized, placebo-controlled, parallel-group study evaluating the&#xD;
      effect of the probiotic on recurrent urinary tract infection (UTI) in adult women recently&#xD;
      treated for UTI.&#xD;
&#xD;
      Primary objective The primary objective is to evaluate the effect of oral supplementation&#xD;
      with probiotic on the frequency of UTI during six months from start of intervention in adult&#xD;
      women with recurrent UTI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">July 12, 2019</completion_date>
  <primary_completion_date type="Actual">July 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blinded, randomized, placebo-controlled, parallel-group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of confirmed UTIs during six months from start of intervention, as compared to placebo</measure>
    <time_frame>6 M</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Recurrent Urinary Tract Infection in Adult Women</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L reuteri</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Probiotic</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give informed consent for participation in the study.&#xD;
&#xD;
          2. Woman aged 18-50 years old at screening.&#xD;
&#xD;
          3. BMI â‰¥18 at screening.&#xD;
&#xD;
          4. Currently on antibiotic treatment for UTI, at the time of screening. Antibiotic&#xD;
             treatment must stop within three days prior to first IP dose.&#xD;
&#xD;
          5. Recurrent UTI defined as at least two UTIs during the last six months or at least&#xD;
             three UTIs during the last 12 months, according to information given by the subject.&#xD;
&#xD;
          6. Able and willing to comply with the restrictions defined for the the study period (see&#xD;
             Section 10.6).&#xD;
&#xD;
          7. Access to Bank ID and ability to use the e-health platform (i.e. Internet access).&#xD;
&#xD;
          8. Ability to understand and comply with the requirements of the study, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal (defined as 12 months of amenorrhoea).&#xD;
&#xD;
          2. Pregnant or breastfeeding.&#xD;
&#xD;
          3. Planning to become pregnant during the study.&#xD;
&#xD;
          4. Irregular menstruations combined with perimenopausal symptoms.&#xD;
&#xD;
          5. Known hypersensitivity or allergy to any of the components of the test product, or to&#xD;
             the comparator (placebo).&#xD;
&#xD;
          6. Use of spermicide contraceptives including spermicidal condom within three days prior&#xD;
             to first IP dose.&#xD;
&#xD;
          7. History of complicated cystitis, urgency incontinence, recent pyelonephritis,&#xD;
             urological and/or gynaecologist abnormalities, immunocompromised, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          8. Unstable bowel disorder such as diarrhoea, Crohn's disease, ulcerative colitis.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healty women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Consultants AB</name>
      <address>
        <city>Uppsala</city>
        <zip>752 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

